TP53 and breast carcinoma: Then, we evaluated the dose-dependent antiproliferative effect of free CUR and RSV vs. EXO-CUR and EXO-RSV in different human breast cell lines, i.e., MCF-7 (p53 wild breast cancer cells), MDA-MB-231 (p53 mutant breast cancer cells), and MCF-10A (non-tumorigenic).